1222 GMT - Roche Holding's research and early development is becoming more productive thanks to the integration of AI into its workflows, but it is too soon to know if the technology improves a drug candidate's chances in a clinical trial, J.P. Morgan analysts say in a research note. The Swiss drugmaker said it is using AI to speed up the process of discovering new medicines, and ultimately aims to improve the quality of those that it moves to the development phase. "While they are making significant progress enhancing the research process, whether this will lead to enhanced probability of success will only become clear as the molecules go through clinical testing over the coming 3-5 years," the analysts say. Shares fall 1.4%.